Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415745 | 0.84 | NPSR1 (0.68) | NPSR1SMN1; SMN2KDM4EHPGDTLR7 | |
| SCHEMBL853400 | 0.82 | NPSR1 (1.00) | NPSR1SMN1; SMN2KDM4EHPGDTLR7 | |
| SCHEMBL854540 | 0.81 | NPSR1 (0.47) | NPSR1TLR7METTHRATHRB | |
| SCHEMBL2846939 | 0.81 | NPSR1 (0.64) | NPSR1SMN1; SMN2KDM4EHPGDTLR7 | |
| SCHEMBL12495497 | 0.78 | SMN1; SMN2 (0.64) | NPSR1SMN1; SMN2KDM4EHPGDDHFR | |
| SCHEMBL2854273 | 0.75 | NPSR1 (0.50) | NPSR1SMN1; SMN2KDM4EHPGDTLR7 | |
| SCHEMBL12495806 | 0.74 | SMN1; SMN2 (0.63) | NPSR1SMN1; SMN2KDM4EHPGDDHFR | |
| SCHEMBL3705743 | 0.74 | NPSR1 (0.65) | NPSR1SMN1; SMN2KDM4EHPGDTLR7 | |
| SCHEMBL2848526 | 0.73 | NPSR1 (0.48) | NPSR1TLR7DHFRTLR8ALDH1A1 | |
| SCHEMBL26050496 | 0.73 | NPSR1 (0.48) | NPSR1SMN1; SMN2KDM4EHPGDTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432768-B1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9533978-B2 | Pyrimidine derivatives and their use in the treatment of cancer and further diseases | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2017-01-03 | — | — | US | disclosed |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA UK LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| EP-2432768-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | AstraZeneca AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133885-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | TYMS, TYMP, DPYD | NPSR1 2520/4885SMN1; SMN2 1637/4885KDM4E 2382/4885 |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | TYMS, TYMP, DPYD | NPSR1 2520/4885SMN1; SMN2 1637/4885KDM4E 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.